Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

122 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor.
Sher T, Yi HF, McBride OW, Gonzalez FJ. Sher T, et al. Biochemistry. 1993 Jun 1;32(21):5598-604. doi: 10.1021/bi00072a015. Biochemistry. 1993. PMID: 7684926
Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs.
Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D. Pineau T, et al. Among authors: sher t. Biochem Pharmacol. 1996 Aug 23;52(4):659-67. doi: 10.1016/0006-2952(96)00340-1. Biochem Pharmacol. 1996. PMID: 8759039
Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.
Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA. Chitta KS, et al. Among authors: sher t. Leuk Lymphoma. 2014 Mar;55(3):652-61. doi: 10.3109/10428194.2013.807927. Epub 2013 Jul 1. Leuk Lymphoma. 2014. PMID: 23721511
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Ailawadhi S, et al. Among authors: sher t. Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6. Leuk Lymphoma. 2012. PMID: 22054286
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Masood A, et al. Among authors: sher t. Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171982 Clinical Trial.
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. Sher T, et al. Br J Haematol. 2011 Jul;154(1):104-10. doi: 10.1111/j.1365-2141.2011.08703.x. Epub 2011 May 9. Br J Haematol. 2011. PMID: 21554260 Free PMC article. Clinical Trial.
A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. ...
A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of borte …
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.
Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Advani PP, et al. Among authors: sher t. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):765-74. doi: 10.1517/17425255.2011.579105. Epub 2011 Apr 27. Expert Opin Drug Metab Toxicol. 2011. PMID: 21521129 Review.
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Sher T, et al. Leuk Lymphoma. 2010 Jan;51(1):85-8. doi: 10.3109/10428190903406806. Leuk Lymphoma. 2010. PMID: 20055660 Clinical Trial.
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Sher T, Miller KC, Lee K, Chanan-Khan A. Sher T, et al. Clin Lymphoma Myeloma. 2009 Aug;9(4):328-30. doi: 10.3816/CLM.2009.n.065. Clin Lymphoma Myeloma. 2009. PMID: 19717386
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Chanan-Khan A, et al. Among authors: sher t. Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460. Leuk Lymphoma. 2009. PMID: 19479618 Clinical Trial.
122 results
Jump to page
Feedback